Mersana Therapeutics, Inc.
MRSN
$0.3879
-$0.0121-3.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 40.50M | 34.84M | 29.94M | 38.30M | 36.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.50M | 34.84M | 29.94M | 38.30M | 36.86M |
| Cost of Revenue | 73.02M | 72.23M | 87.96M | 119.68M | 148.27M |
| Gross Profit | -32.52M | -37.39M | -58.02M | -81.38M | -111.41M |
| SG&A Expenses | 40.81M | 42.06M | 45.09M | 52.78M | 59.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.83M | 114.29M | 133.05M | 172.46M | 207.81M |
| Operating Income | -73.34M | -79.45M | -103.11M | -134.16M | -170.96M |
| Income Before Tax | -68.77M | -74.20M | -104.77M | -134.81M | -171.67M |
| Income Tax Expenses | 418.00K | 418.00K | -- | -- | -- |
| Earnings from Continuing Operations | -69.19 | -74.62 | -104.77 | -134.81 | -171.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.19M | -74.62M | -104.77M | -134.81M | -171.67M |
| EBIT | -73.34M | -79.45M | -103.11M | -134.16M | -170.96M |
| EBITDA | -71.71M | -77.78M | -101.41M | -132.54M | -169.44M |
| EPS Basic | -0.57 | -0.61 | -0.86 | -1.14 | -1.50 |
| Normalized Basic EPS | -0.35 | -0.38 | -0.50 | -0.67 | -0.89 |
| EPS Diluted | -0.57 | -0.61 | -0.87 | -1.14 | -1.50 |
| Normalized Diluted EPS | -0.35 | -0.38 | -0.50 | -0.67 | -0.89 |
| Average Basic Shares Outstanding | 490.15M | 487.20M | 485.00M | 478.17M | 464.26M |
| Average Diluted Shares Outstanding | 490.15M | 487.20M | 485.00M | 478.17M | 464.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |